The investigational BTK inhibitor fenebrutinib was as effective as the approved therapy Ocrevus (ocrelizumab) at reducing the risk of disability progression in people with primary progressive multiple sclerosis (PPMS), meeting the main goal of a Phase 3 trial. According to fenebrutinib’s developer, Genentech, the therapy is the first in more than 10 years to slow disability […]
The post ACTRIMS 2026: Fenebrutinib matches Ocrevus in PPMS trial appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com